

Rhythm Continues Platform Expansion Program for Other Cancers

Highlights

- ✓ Rhythm appoints **Nexomics**, at Peter MacCallum Cancer Centre as its third bioanalytical partner to advance the development program for platform expansion into gastric cancer;
- ✓ This partnership follows the engagement of Agilex Biolabs (breast cancer) and the Baker Institute (lung cancer);
- ✓ These appointments cover three of Rhythm's additional cancer market opportunities identified outside the ColoSTAT® program; and
- ✓ Short list of candidate biomarkers with potential use in the early detection of breast, lung, gastric, cervical and pancreatic cancers have been identified. These will now be evaluated for the early-stage proof-of-concept research with our bioanalytical partners.

Transformative cancer diagnostics technology company, Rhythm Biosciences Ltd (**ASX: RHY**) (**Rhythm** or the **Company**) is pleased to provide an update regarding the technical feasibility pipeline expansion initiatives / opportunities.

As previously announced, the Company has identified several other critical cancers where it can leverage its diagnostics technology platform and has commenced biomarker identification and feasibility programs for each. In July 2022, Rhythm announced bioanalytical partner Agilex Biolabs and in December 2022 the Baker Institute who are engaged to support the development of the first two cancer programs.

Partnership with Nexomics

Rhythm has further progressed its feasibility programs, now confirming a third bioanalytical partner, Nexomics, at Peter MacCallum Cancer Centre (PMCC), who have been engaged to advance proof of concept R&D for a third cancer program, gastric cancer.

Nexomics provides technical expertise for assessment of new diagnostic biomarkers against a "gold standard". They offer a broad range of clinical tests for inclusion, safety monitoring, efficacy and exploratory biomarkers analysis using unparalleled access to clinical pathology samples.

PMCC is a world leading cancer treatment and research centre, whose values align with Rhythm's goal of reducing worldwide cancer burden through early detection. PMCC will focus on feasibility and testing of preferred biomarker combinations with the greatest potential for early detection of gastric cancer.

Directors

Dr. Trevor Lockett, Technical Director & Board Member of Rhythm, commented:

"We are truly excited to work with an internationally recognised company such as Nexomics & Peter MacCallum Cancer Centre, that both understands the technology, shares the visions, and sees the significant opportunity to positively impact lives globally. This partnership strengthens our ability to leverage strong bioanalytical expertise to assess options for advancing our technology platform, while in parallel, the Company focuses its internal resources on accelerating our initial entry for ColoSTAT into international markets. We are looking forward to working with Nexomics to potentially identify an early screening test for gastric cancer in the future."

- ENDS -

Authorisation & Additional Information

This announcement was authorised by the Board of Directors of Rhythm Biosciences Limited.

For further information contact us via investor@rhythmbio.com or on +61 3 8256 2880:

Mr. Otto Buttula Executive Chairman	Dr. Trevor Lockett Technical Director	Mr. Paul Smith CFO & Company Secretary
---	---	--

About Rhythm Biosciences

Rhythm Biosciences Ltd (ASX: RHY) is an Australian innovative, medical diagnostics company aimed at delivering simple, affordable blood tests for accurate and early detection of cancers. Rhythm is focused on improving patient outcomes through detection at the earliest possible stage, reducing the global burden of cancer and saving lives.

Rhythm Biosciences is committed to working with likeminded global partners to achieve commercialisation and distribution of these simple solutions.

The company was founded in 2017 and is headquartered in Melbourne, Australia. For more information, visit rhythmbio.com and follow the company on LinkedIn and Twitter.

About ColoSTAT®

Colorectal cancer (CRC), also referred to as bowel cancer, is the second leading cause of cancer deaths globally. If diagnosed early, colorectal cancer is curable.

The ColoSTAT® Test-Kit is Rhythm Bioscience's simple blood test for the detection of CRC. It measures five specific protein biomarkers that indicate the likelihood presence of CRC. The test can be used as an alternative for individuals who are unable or unwilling to participate in current screening programs.

The ColoSTAT® Test-Kit is based on research from Australia's CSIRO and is patent protected internationally. It has the potential to play a key role in reducing the mortality rate and healthcare costs associated with colorectal cancer.

About Nexomics

Nexomics (powered by Peter MacCallum Cancer Centre) provides technical expertise for assessment of new diagnostic biomarkers against a "gold standard". They offer a broad range of clinical tests for inclusion, safety monitoring, efficacy and exploratory biomarkers analysis using unparalleled access to clinical pathology samples.

About Peter MacCallum Cancer Centre

Peter MacCallum Cancer Centre is a world leading cancer research, education and treatment centre and Australia's only public health service solely dedicated to caring for people affected by cancer. We have 3,300 staff, including more than 750 laboratory and clinical researchers, all focused on providing better treatments, better care and potential cures for cancer.